However, increased levels of CXCL13 in tumor tissues have been suggested to be associated with a better response to anti–PD-(L)1 therapy (41), which may limit the utility of the CXCL13-targeting strategy as an option for irAE management, because of the risk of attenuating antitumor immunity. The gene discussed is CXCL13; the disease is neoplasm.